Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLRBNASDAQ:KTOVNASDAQ:NVLNNASDAQ:RGLSNASDAQ:TOCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$3.03-0.3%$3.68$1.33▼$4.45$97.75M0.921.70 million shs806,966 shsKTOVPurple Biotech$0.46+7.0%$4.16$2.20▼$14.40$7.25M2.371.18 million shs171,410 shsNVLNNovelion Therapeutics$0.70$0.54▼$2.35$13.77M2.12190,529 shs26,947 shsRGLSRegulus Therapeutics$2.13-4.1%$2.12$1.08▼$3.79$139.43M1.572.55 million shs222,749 shsTOCATocagen$0.78+5.4%$32.24$0.42▼$6.77$18.66M0.011.47 million shs57,459 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-5.30%-18.06%-19.58%-12.64%+96.76%KTOVPurple Biotech+6.15%-25.04%-35.01%-29.08%-77.51%NVLNNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%RGLSRegulus Therapeutics-5.13%-20.14%-6.92%+81.97%+79.03%TOCATocagen+5.41%+8.33%+18.18%+12.13%-26.42%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences1.6308 of 5 stars3.52.00.00.03.30.00.6KTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics2.321 of 5 stars4.42.00.00.02.11.70.0TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences3.00Buy$20.00560.07% UpsideKTOVPurple BiotechN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25240.38% UpsideTOCATocagenN/AN/AN/AN/ACurrent Analyst RatingsLatest TOCA, NVLN, RGLS, CLRB, and KTOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/AKTOVPurple Biotech$1M7.25N/AN/A$5.56 per share0.08NVLNNovelion Therapeutics$130.43M0.00N/AN/A($4.69) per share0.00RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ATOCATocagen$40K466.42N/AN/A$0.45 per share1.73Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ANVLNNovelion Therapeutics-$108.33MN/A0.00N/AN/A-79.43%N/A-26.13%N/ARGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ALatest TOCA, NVLN, RGLS, CLRB, and KTOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A0.810.81KTOVPurple BiotechN/A2.22N/ANVLNNovelion TherapeuticsN/A0.240.21RGLSRegulus TherapeuticsN/A3.313.31TOCATocagen1.881.151.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%KTOVPurple Biotech30.72%NVLNNovelion Therapeutics35.00%RGLSRegulus Therapeutics92.38%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences4.60%KTOVPurple Biotech2.98%NVLNNovelion Therapeutics3.60%RGLSRegulus Therapeutics8.41%TOCATocagen10.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences2032.26 million30.78 millionOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableNVLNNovelion Therapeutics10919.62 millionN/AOptionableRGLSRegulus Therapeutics3065.46 million59.96 millionOptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, NVLN, RGLS, CLRB, and KTOV HeadlinesSourceHeadlineGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizpharmiweb.com - March 25 at 4:25 AMONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Gliomaascopubs.org - February 12 at 6:14 PMMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorseurekalert.org - January 20 at 12:14 AMForte Biosciences: Changes In Registrant S Certifying Accountantcbonds.com - December 12 at 8:27 AMRiskOn International And 3 Other Stocks Under $2 Insiders Are Buyingmarkets.businessinsider.com - December 11 at 9:20 AMPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedpharmaceutical-technology.com - November 6 at 9:33 AMProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointmentfinance.yahoo.com - November 2 at 10:33 AMFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma Patientsprecisionmedicineonline.com - July 26 at 11:09 PMGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRnews.google.com - May 12 at 8:33 AMForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comnews.google.com - April 29 at 12:45 AMGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comnews.google.com - April 6 at 8:25 PMBelzutifan plus cabozantinib for patients with advanced clear cell ... - The Lancetnews.google.com - March 31 at 11:10 PMCurrent drug development and trial designs in neuro-oncology ... - The Lancetnews.google.com - March 28 at 12:07 AMCompanion Diagnostics Market is set to experience a significant ... - Digital Journalnews.google.com - March 27 at 8:37 AMOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital Journalnews.google.com - March 14 at 4:44 PMAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital Journalnews.google.com - March 8 at 10:39 AMAnaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan Newsnews.google.com - March 2 at 1:05 PMAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029marketwatch.com - February 28 at 3:22 AMCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029marketwatch.com - February 27 at 9:31 AMAn echo through brain cancer’s empty pipelinepharmaphorum.com - February 7 at 7:04 PMCompanion Diagnostics Market Size, Share, Growth Statistics By ... - Digital Journalnews.google.com - February 3 at 6:12 AMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo Financenews.google.com - February 2 at 1:10 PMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR Newswirenews.google.com - February 2 at 8:09 AMHuman Resource Management Market Booming Worldwide With ... - Rejoice Magazinenews.google.com - January 27 at 11:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Novelion TherapeuticsNASDAQ:NVLNNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.